Metagenomi Therapeutics, Inc.
Data quality: 100%
MGX
Nasdaq
Manufacturing
Chemicals
$1.38
▼
$0.02
(-1.08%)
Mkt Cap: 51.73 M
Price
$1.38
Mkt Cap
51.73 M
Day Range
$1.35 — $1.41
52-Week Range
$1.25 — $3.95
Volume
106,073
Open $1.36
50D / 200D Avg
$1.50
8.06% below
50D / 200D Avg
$1.90
27.47% below
Quick Summary
Key Takeaways
Negative free cash flow of -89.47 M
Capital efficient — spends only 2.28% of revenue on capex
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)-51.79%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-46.95%
Above sector avg (-53.47%)
ROIC-33.17%
Net Margin-348.54%
Op. Margin-380.85%
Safety
Debt / Equity
N/A
Current Ratio6.42
Interest CoverageN/A
Valuation
PE (TTM)
-0.59
Above sector avg (-1.47)
P/B Ratio0.29
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.6 | -1.5 |
| P/B | 0.3 | 1.6 |
| ROE % | -47.0 | -53.5 |
| Net Margin % | -348.5 | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -51.79% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 25.21 M | Net Income (TTM) | -87.87 M |
| ROE | -46.95% | ROA | -33.78% |
| Gross Margin | N/A | Operating Margin | -380.85% |
| Net Margin | -348.54% | Free Cash Flow (TTM) | -89.47 M |
| ROIC | -33.17% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 6.42 |
| Interest Coverage | N/A | Asset Turnover | 0.10 |
| Working Capital | 160.24 M | Tangible Book Value | 178.45 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.59 | Forward P/E | N/A |
| P/B Ratio | 0.29 | P/S Ratio | 2.05 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -172.95% | ||
| Market Cap | 51.73 M | Enterprise Value | 18.96 M |
| Per Share | |||
| EPS (Diluted TTM) | -2.36 | Revenue / Share | 0.67 |
| FCF / Share | -2.38 | OCF / Share | -2.36 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 2.28% | FCF Conversion | 101.82% |
| SBC-Adj. FCF | -103.68 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | 25.21 M | 52.30 M |
| Net Income | -87.87 M | -78.06 M |
| EPS (Diluted) | -2.36 | -2.36 |
| Gross Profit | — | — |
| Operating Income | -96.01 M | -88.90 M |
| EBITDA | — | — |
| R&D Expenses | 94.43 M | 109.18 M |
| SG&A Expenses | — | — |
| D&A | — | — |
| Interest Expense | — | — |
| Income Tax | -58,000.0 | -5.51 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Total Assets | 221.10 M | 324.60 M |
| Total Liabilities | 62.51 M | 89.74 M |
| Shareholders' Equity | 158.60 M | 234.86 M |
| Total Debt | — | — |
| Cash & Equivalents | 41.72 M | 27.39 M |
| Current Assets | 165.54 M | 257.96 M |
| Current Liabilities | 22.93 M | 37.31 M |
{"event":"ticker_viewed","properties":{"ticker":"MGX","listing_kind":"stock","pathname":"/stocks/mgx","exchange":"Nasdaq","country":"US"}}